FY2025 EPS Estimates for Gilead Sciences Boosted by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Gilead Sciences in a note issued to investors on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will post earnings of $8.05 per share for the year, up from their prior forecast of $7.96. Cantor Fitzgerald currently has a “Overweight” rating and a $125.00 price target on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Cantor Fitzgerald also issued estimates for Gilead Sciences’ FY2026 earnings at $9.40 EPS.

A number of other equities research analysts have also issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Morgan Stanley boosted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Finally, Oppenheimer lowered their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $111.38.

Gilead Sciences Stock Up 1.1%

GILD stock opened at $114.54 on Thursday. Gilead Sciences has a 52-week low of $68.14 and a 52-week high of $119.96. The company’s 50 day simple moving average is $107.62 and its 200-day simple moving average is $104.50. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The firm has a market capitalization of $142.48 billion, a P/E ratio of 24.11, a P/E/G ratio of 0.73 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the business earned ($1.32) earnings per share. The firm’s revenue was down .3% compared to the same quarter last year.

Institutional Trading of Gilead Sciences

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. FMR LLC raised its stake in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP raised its stake in Gilead Sciences by 3.1% during the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock valued at $3,293,822,000 after purchasing an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC raised its stake in Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock valued at $2,608,337,000 after purchasing an additional 749,047 shares during the last quarter. Finally, Norges Bank acquired a new position in Gilead Sciences during the 4th quarter valued at $1,789,254,000. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $330,510.00. Following the completion of the sale, the insider directly owned 120,168 shares of the company’s stock, valued at approximately $13,238,908.56. This represents a 2.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $275,425.00. Following the sale, the chief financial officer directly owned 165,110 shares of the company’s stock, valued at approximately $18,190,168.70. This represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 58,500 shares of company stock valued at $6,340,745. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.76%. The ex-dividend date was Friday, June 13th. Gilead Sciences’s dividend payout ratio is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.